BioSpace News Archive

Therapix Biosciences Ltd. (Nasdaq: TRPX) (the “Company” or “Therapix”), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today receipt of Notice of Delisting and Injunction from Israeli Court. Notice of Delisting On June 30, 2020 , Therapix Biosci

Company Expects to Report Topline Phase 3 LOGICS Study Results During the Third Quarter of 2020

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that a peer-reviewed article published in Clinical Cancer Research (Clin Cancer Res June 30 2020 DOI:10.1158/1078-0432.CCR-19-4092) reported findings that Moleculin’s STAT3 inhibitor,

Sherlock Biosciences and binx health today announced the companies have entered into a strategic partnership to develop the world’s first rapid, point-of-care diagnostic test for COVID-19 leveraging CRISPR technology. The organi

eGenesis, a biotechnology company using breakthrough gene editing technologies for the development of safe and effective human-compatible organs, tissues, and cells to address the global organ shortage, today announced that Peter Hanson, DVM, Ph.D., has been appointed as Chief Operating Officer (COO). Dr. Hanson will assume responsibility for directing eGenesis’ day-to-day organizational and operational activities including production and man

- Phase 2b CONTROL study is evaluating TMB-001 (topical isotretinoin) in subtypes of rare genetic keratinization disorder - - Company also advancing Phase 2b clinical trial evaluating TMB-002 (topical rapamycin) for treatment of facial angiofibromas in tuberous sclerosis complex with 70% of trial sites now open - WOODCLIFF LAKE, N.J., July 01, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical co

Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences Company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnolog

Stability Biologics®, LLC, an innovative, regenerative medicine company that provides advanced biologic products to improve patient care and well–being, announced today that the Centers for Medicare and Medicaid Services (CMS) has assigned a unique product Q-code under the Healthcare Common Procedure Coding System (HCPCS) for AmnioCore.

Antengene Corporation today announced its appointment of Zhinuan Yu, Ph.D., as Corporate Vice President (CVP) of Biometrics and Regulatory Enabling Functions. Zhinuan will be responsible for providing statistical leadership and strategic regulatory input for company’s projects and will report directly to Dr. Jay Mei , Cha

Cambrex, the leading small molecule company providing drug substance, drug product, and analytical services across the entire drug lifecycle, announced that it is investing $3.6 million at its Karlskoga, Sweden facility to increase flexible drug substance manufacturing capacity.